Meril Launches MyClip, India's First Transcatheter-Edge-to-Edge Repair (TEER) System for Treatment of Severe Mitral Regurgitation
Meril Life Sciences, a leading global med-tech company, marked a significant milestone with the launch of MyClip, India's first Transcatheter Edge-To-Edge Repair (TEER) system, on June 14. The landmark Structural Heart Innovation event, held at Meril Academy, Vapi (Gujarat) from June 13–15, brought together over 150 Indian interventional cardiologists along with cardiac imaging expert and international stalwarts, including Prof. Ottavio Alfieri ('Father of mitral valve repair'), Prof. Francesco Maisano, and Prof. Agricola, joining global pioneers in edge-to-edge mitral valve repair.Meril is currently the world's leading TAVI group following the success of Myval THV and first Indian company to introduce a TEER system, placing the country firmly on the map as an innovator in transcatheter heart valve therapies (with both replacement and repair technology platforms). MyClip introduction demonstrates India's growing capabilities in structural heart solutions and reflects Meril's commitment to accessible cutting-edge cardiac care.MyClip TEER System is designed for patients suffering from severe Mitral Regurgitation (MR) who are at high surgical risk due to pre-existing issues like hypertension, diabetes, obesity, advanced age, physical frailty, enlarged or weak heart, and patients with kidney, lung and liver problems. MR, particularly if untreated, has a devastating mortality rate—over 50% of patients may not survive without timely intervention, and 1-year mortality can be as high as 57%.The MyClip TEER System enables precise closure of the mitral valve flaps, effectively preventing the backward flow of purified blood into the lungs. The procedure is minimally invasive, & takes approximately one hour, and allows patients to return home within 3–5 days. After discharge, patients can resume daily activities like walking and non-strenuous work within a short period post the procedure.According to the landmark COAPT Study published in the New England Journal of Medicine (NEJM), patients receiving device-based therapy for mitral regurgitation experienced significantly better outcomes compared to those receiving standard medical treatment. Within 24 months, the hospitalization rate for heart failure was reduced to 35.8% per patient-year in the device group, compared to 67.9% in the control group. Additionally, mortality within the same period was notably lower in the device group, at 29.1%, compared to 46.1% in the control group.Currently, approximately 150 TEER (Transcatheter Edge-to-Edge Repair) procedures are performed annually in India, with the majority of patients falling in the younger age group (30 – 60). These statistics bring to light a pressing need for early and effective intervention in younger demographics.The launch of MyClip TEER System marks a transformative moment for structural heart therapy in India. Transcatheter Edge-to-Edge Repair (TEER) therapy has shown significant success over traditional Guideline Directed Medical Therapy (GDMT). MyClip represents a major step forward in India's cardiovascular treatment landscape. In his inaugural speech, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, said, 'In India, around 1.5 million people are known to have severe mitral regurgitation. Of these at least 1.2 million are post myocardial infarction (MI or a heart attack) or due to heart failure. Introduction of the MyClip TEER system marks a pivotal shift and we're witnessing early adoption. Meril's efforts in training cardiologists and building TEE-based imaging expertise are crucial steps in scaling this life-saving therapy across the country."'With MyClip, Meril is reshaping the country's role in global medtech. This homegrown innovation is a testament to what Indian science, engineering, and clinical collaboration can achieve together. Meril's nationwide public awareness campaign #TreatmentZarooriHai is in full swing, with brand ambassador MS Dhoni, to educate patients and families about the life-saving value of timely intervention in mitral valve regurgitation,' Mr. Bhatt added.The two-day Structural Heart Innovation scientific program featured case demonstrations, interactive hands-on workshops, and the presentations leading Interventional Cardiologists and Echocardiologists. The event concluded with a call to build a sustainable M-TEER ecosystem in India, focused on accessibility, clinical excellence, and continuous innovation.Disclaimer: The material and information contained are for advertorial purposes only. India Today holds no responsibility for the content written on the website as a basis for making any business, legal, or any other decision. Any reliance placed on such material is at your own risk.- Ends
advertisement
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
34 minutes ago
- First Post
Wegovy launched in India: How the breakthrough drug triggers weight loss
Danish drugmaker Novo Nordisk has launched its popular weight-loss drug Wegovy in India, months after its rival Mounjaro's entry into the Indian market. Semaglutide, which is sold under the brand name Wegovy, suppresses appetite and regulates blood sugar, leading to weight loss. But is it better than the US-based pharmaceutical company Eli Lilly's product available in the country since March? read more After Mounjaro, another weight loss jab has made its entry into Indian markets. Danish drugmaker Novo Nordisk on Tuesday (June 24) launched its popular weight-loss drug Wegovy in India. The drug semaglutide, marketed under the brand name Wegovy, will be available in the form of injections to be administered once a week. Weight-loss drugs like Ozempic, Mounjaro and Wegovy have become all the rage. As another 'weight loss miracle drug' becomes available in India, we take a look at what it is and how it works. STORY CONTINUES BELOW THIS AD What is Wegovy? Wegovy (semaglutide) is a prescription drug to tackle obesity and reduce cardiovascular risks. Semaglutide suppresses appetite and has long been used to treat diabetes. In recent years, the drug has been prescribed as a weight-loss medication after research revealed it was quite effective in helping people lose weight. Semaglutide is used in Wegovy and the highly popular type 2 diabetes treatment Ozempic . How does Wegovy work? Semaglutide in Wegovy works as an appetite suppressant by imitating a hormone called glucagon-like peptide-1 (GLP-1). It is an intestinal hormone released after eating, and usually makes people feel fuller. Semaglutide also brings down the rate at which food moves from the stomach to the intestines, making one feel full for longer and reducing blood sugar levels, as per a Healthline article. Wegovy is prescribed as a weekly injection through pre-filled pens that can be administered by the patient into their upper arm, thigh or stomach. Wegovy pens are sorted at a packaging line at Novo Nordisk's facility in Hillerod, Denmark, March 8, 2024. File Photo/Reuters Initially, a low dose is usually suggested, which is gradually hiked until a higher maintenance dose is reached, reported BBC. Along with exercise and a low-calorie diet, Wegovy could reduce the risk of cardiovascular problems, such as heart attack and stroke. The drug is prescribed to adults with cardiovascular disease who are overweight or obese, as per the Healthline article. Wegovy in India Wegovy has made its way to India. The drug is under distribution and will be available in pharmacies by the end of the month, Vikrant Shrotriya, Novo Nordisk's India managing director, told Reuters. Wegovy will be sold in India in five doses — 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. The first three doses will cost Rs 4,366 weekly, totalling Rs 17,345 per month. The 1.7 mg dose will be priced at Rs 24,280 monthly, while the 2.4 mg dose will cost Rs 26,015 per month, the Danish company announced. STORY CONTINUES BELOW THIS AD Wegovy vs Mounjaro Wegovy's launch in India comes just a few months after US-based pharmaceutical company Eli Lilly introduced Mounjaro in the South Asian country. Chemically known as tirzepatide, Mounjaro , a diabetes and weight-loss drug, was rolled out in March. It is the first drug in its class to activate both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) hormones that regulate blood sugar. Wegovy and Ozempic (both brand names for semaglutide) only mimic the hormone GLP-1. Wegovy is only approved for weight loss. Mounjaro has received official approval for the treatment of Type 2 diabetes and weight loss in obese and overweight people. A trial of both drugs found that Mounjaro is more effective than Wegovy. While they both led to a significant weight loss, Mounjaro caused a 20 per cent weight reduction than Wegovy's 14 per cent after 72 weeks of treatment. 'Mounjaro (tirzepatide) generally outperforms Wegovy (semaglutide) for weight loss, achieving up to about 15-20 body weight reduction (due to its dual GLP-1 and GIP action) compared to Wegovy's 14-17 per cent in trials,' Dr Anoop Misra, a renowned endocrinologist, told News18. STORY CONTINUES BELOW THIS AD However, he added, 'Wegovy is [US Food and Drug Administration] FDA-approved for chronic weight management and cardiovascular risk reduction, with broader access for non-diabetic weight loss and adolescent use, while Mounjaro is primarily approved for diabetes (used off-label for weight loss)." Wegovy's launch is expected to set off competition with Mounjaro in the Indian market. 'India represents a potentially massive structural growth opportunity for GLP-1 drugs, but current penetration remains minimal. Eli Lilly has taken the lead by launching Mounjaro in India—one of the most successful product launches in the Indian market so far," Vishal Manchanda, a pharma analyst at the financial services firm Systematix, was quoted as saying by News18. As of May, Mounjaro has sold more than 81,570 units in India, worth about Rs 24 crore, according to data from research firm PharmaTrac. Indian drugmakers are also rushing to develop cheaper versions of the weight-loss drugs to penetrate the market, which is estimated to be around $150 billion by the early 2030s. STORY CONTINUES BELOW THIS AD With inputs from agencies
Time of India
2 hours ago
- Time of India
Rewriting the health playbook: How Abu Dhabi is scaling AI and digital care
In April 2025, global health leaders, policymakers, innovators, and researchers convened for Abu Dhabi Global Health Week (ADGHW)—a flagship initiative of the Department of Health – Abu Dhabi (DoH). Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, the year-round global platform advances transformative solutions across health and life sciences. Health doesn't operate in a silo; it calls for critical thinking and collaboration among practitioners, policymakers, pharmaceutical leaders, researchers, and frontline healthcare workers accelerating shared health ambitions worldwide. The 2025 theme, 'Towards Longevity: Redefining Health and Well-being,' mirrors ADGHW's ambition: shifting from episodic treatment to continuous, preventive, and personalised care. The promise of digital health and AI One pressing theme that has dominated the public health discourse in the past few years is digital health and artificial intelligence (AI). Advanced technologies are unlocking new frontiers by improving access, enhancing clinical outcomes, and supporting more resilient health systems. From remote monitoring, AI-diagnostics, to telemedicine and predictive analysis, Abu Dhabi is reimagining care pathways to deliver personalised treatment while empowering providers with real-time, data-driven insights. ET Spotlight H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi According to H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, 'Digital health allows us to tailor care to the needs of each individual while improving access across diverse communities. Whether through telemedicine platforms or data-enabled prevention strategies, our focus is on strengthening system resilience and enhancing patient outcomes.' Abu Dhabi's growing trust-based health data and technical infrastructure presents a fertile ground for innovation. Initiatives such as Malaffi, the region's first Health Information Exchange, and the Emirati Genome Program are central to this vision. While the former facilitates real-time data sharing among care providers, the latter creates a unique dataset to analyse genetic predispositions to build better individual and population-level responses in health management. Live Events India's interest in scaling population health genomics (through initiatives such as the Genome India project, which aims to map the genetic diversity of the Indian population) aligns with such frameworks in Abu Dhabi. Data governance, ethical AI usage, and consent frameworks are some of the fronts where cross-border collaboration could be envisioned. Innovation Through Strategic Initiatives Initiatives announced at ADGHW 2025 reflect Abu Dhabi's role as a global health innovation leader, unveiling a suite of bold new initiatives that move digital health from concept to execution. Notably, the launch of the Health, Endurance, Longevity, and Medicine (HELM) Cluster—a partnership between the Abu Dhabi Investment Office, Mohamed bin Zayed University of Artificial Intelligence, and Hub71—signals a bold step toward advancing health life sciences, R&D, and building a robust ecosystem for medical innovation, pharmaceutical manufacturing, and biotechnology. The Startup Zone and Smart Health Hackathon spotlighted emerging innovators tackling real-world health challenges through AI-powered and digital-first approaches. The inaugural ADGHW Innovation Awards were also introduced, recognising breakthroughs that are driving meaningful improvements in patient outcomes, healthcare accessibility, and system efficiency. A human-centred approach to innovation However, digital transformation in healthcare transcends the technological realm. It must be rooted in the realities of patients and on-ground experiences that have emerged from years of clinical practice. Dr. Asma Al Mannaei, Executive Director of the of the Health Life Sciences Sector at the Department of Health – Abu Dhabi, underscores its impact; 'The future of health is patient-centred. Technology is a powerful enabler, but the true impact comes when innovations align with human need.' Technologies shown at ADGHW are shifting health towards proactive and predictive models of care, helping individuals manage chronic conditions, while algorithms interpret patient data to identify health risks before they escalate. B uilding a future-ready healthcare workforce The success of this transformation depends equally on human capital. As AI and digital tools become more embedded in health workflows, there is a growing need for skilled professionals who can operate in hybrid, tech-enabled environments. 'Investing in workforce development is key to realising the benefits of digital health,' notes Dr. Rashed Obaid Al Suwaidi, Director General of the Abu Dhabi Public Health Centre (ADPHC) . 'Our role is to ensure that future clinicians and allied health professionals are equipped with both clinical and digital competencies, ensuring a seamless integration of innovation into care delivery.' This is true in the context of India as well, as it seeks to upskill its healthcare workforce to adopt emerging technologies. Abu Dhabi's initiatives present a model for India's academic and public-private institutions. The focus is on supporting the development of an AI-trained workforce capable of advancing both diagnostic precision and operational efficiency. Public health, equity, and global collaboration ADGHW 2025 also steered conversations on policy innovation, to drive an actionable agenda across global collaborators. A major milestone was the launch of a Global Declaration on Longevity and Precision Health, outlining an actionable agenda to extend both lifespan and healthspan through international cooperation and innovation, placing longevity at the heart of global health priorities. The Department of Health – Abu Dhabi (DoH) also signed a landmark Memorandum of Understanding (MoU), which focuses on advancing precision medicine and genomics in oncology, rare genetic disorders, and metabolic diseases, leveraging AI and collaborative research to pioneer new treatment pathways. This multi-stakeholder partnership included PureHealth, M42, Illumina, Khalifa University (KU), New York University Abu Dhabi (NYUAD), and the Institute for Healthier Living Abu Dhabi (IHLAD). In a world-first, Abu Dhabi unveiled the AI-powered Population Health Intelligence Framework—a learning health system designed to continuously predict, prevent, and respond to public health challenges through AI and real-time analytics. 'Public health must be inclusive, data-informed, and anticipatory,' says H.E. Dr. Rached Obaid Al Suwaidi, Director-General of Abu Dhabi Public Health Center (ADPHC). 'Through ADGHW, we are advocating for integrated approaches that connect population health strategies with emerging digital tools.' This intersection of innovation and inclusion is critical as healthcare systems globally face challenges of scale, access, and sustainability. Through these measures, Abu Dhabi is positioning itself as both a contributor and convener in shaping the global health agenda. Infrastructure for impact Technology alone does not deliver transformation, it must be embedded within systems designed for agility, interoperability, and scale. Ibrahim Al Jallaf, Division Director of Digital Health at DoH, underscores that 'Our focus is on integrating digital health tools into a unified ecosystem. Whether it's through regulatory frameworks, investment incentives, or data platforms, we are building the infrastructure to support sustained impact.' ADGHW also provides the economic foundation for this transformation. By 2045, Abu Dhabi's life sciences sector is projected to contribute over AED 94 billion to GDP and generate more than 30,000 jobs. This economic vision is tightly interlinked with the health innovation agenda, making the Emirate a compelling hub for Indian health tech startups seeking Middle East expansion. From Abu Dhabi to the world As a year-round platform, ADGHW fosters a strategic bridge between global health priorities and local capacity, creating a space where data, expertise, and ambition converge. For leaders across government, academia, industry, and civil society, it presents an opportunity to co-create solutions that resonate far beyond borders, enhancing health outcomes not only for individuals but for entire communities and nations.
Business Standard
2 hours ago
- Business Standard
Tetley Launches Tetley Green Tea Slim Care, First Ever Green Tea with Added L-Carnitine, a Natural Nutrient Proven to Burn Body Fat
NewsVoir Bangalore (Karnataka) [India], June 24: Tetley Green Tea, one of India's most trusted Green Tea brands under Tata Consumer Products, today announced the launch of two breakthrough green tea variants -- Tetley Green Tea Slim Care with added L-Carnitine and Tetley Green Tea Beauty Care with added Biotin -- redefining what green tea means for the modern Indian consumer. These are not just regular green teas. With proven ingredients and great taste, the new range is built to deliver real benefits -- L-Carnitine is a natural nutrient proven to burn body fat while Biotin is a natural vitamin known to support beautiful hair and glowing skin. Leading the charge is Kriti Sanon, actor, wellness enthusiast, and the new face of Tetley Green Tea's wellness portfolio. As the brand ambassador, Kriti, known for her love of fitness and healthy living, brings alive the proven efficacy of these science backed natural ingredients, with the vibrant new #NotYourRegularGreenTea campaign. Link to the film: "Tetley Green Tea Slim Care isn't your regular green tea -- and that's exactly why I love it. It's powered by L-Carnitine, a natural nutrient proven to burn body fat. For someone like me, always on the move, this blend of flavour and function fits right in. It's smart, simple, refreshing, purposeful and makes every cup count," adds Kriti. With added L-Carnitine and Biotin, Tetley has crafted green teas that are in line with the category's evolution towards holistic wellness. Both variants are designed to help address real consumer needs -- weight management and skin & hair health-- while offering a refreshing and enjoyable green tea experience. Puneet Das, President - Packaged Beverages, India & South Asia, Tata Consumer Products, added, "Consumers today are looking for more from their everyday wellness choices -- they want efficacy with enjoyment. Tetley Green Tea Slim Care and Beauty Care are tailored for this evolving mindset. With functional ingredients backed by science, we are offering green teas that not only taste great but also support consumer's wellness goals. These are truly not just regular green teas." Arpan Bhattacharyya, Executive Director - Head of Creative (South) at MullenLowe Lintas said, "Green tea with added L-Carnitine is new news in the category. Our attempt was to bring alive the new proposition with a deep-rooted consumer insight of how even for celebrities, like Kriti Sanon, the best laid wellness and fitness plans are hard to stick to in everyday life. We crafted slice of life moments and positioned the new Tetley Green Tea with added L-Carnitine as a solid modern wellness companion with proven efficacy. Kriti's charm and authenticity adds relatability to the campaign, and we hope that it resonates with the consumer." Both Tetley Green Tea Slim Care and Tetley Green Tea Beauty Care are available across major retail stores and e-commerce platforms nationwide. This launch reaffirms Tetley's position as a category pioneer -- blending innovation, functionality, and lifestyle relevance in every sip. Tata Consumer Products Limited is a focused consumer products company uniting the principal food and beverage interests of the Tata Group under one umbrella. The Company's portfolio of products includes tea, coffee, water, RTD, salt, pulses, spices, ready-to-cook and ready-to-eat offerings, breakfast cereals, snacks and mini meals. Its key beverage brands include Tata Tea, Tetley, Organic India, Eight O'Clock Coffee, Tata Coffee Grand, Himalayan Natural Mineral Water, Tata Copper+ and Tata Gluco+. Its foods portfolio includes brands such as Tata Salt, Tata Sampann, Tata Soulfull, Ching's Secret and Smith & Jones. In India, Tata Consumer Products has a reach of over 275 million households, giving it an unparalleled ability to leverage the Tata brand in consumer products. The Company has a consolidated annual turnover of ~Rs. 17,618 Crs with operations in India and International markets.
